MedinCell announces the launch of phase 3 of F14 (mdc-CWM), the first localized treatment aimed at relieving pain for several weeks after total knee replacement surgery
Euronext: MEDCL Montpellier – France November 7, 2022 – 7:00 p.m. CET
• The study is conducted in the United States and funded by MedinCell’s partner, Arthritis Innovation Corporation (AIC)
• F14 (mdc-CWM) is an extended-release formulation of the non-steroidal anti-inflammatory drug (NSAID), celecoxib, administered into the joint at the time of knee replacement
• mdc-CWM aims to facilitate patient recovery by providing pain relief for several weeks and improving functional recovery, while reducing opioid consumption
can lead to addiction
• The Phase 3, multicenter, randomized, double-blind, 150-patient safety and efficacy trial was designed in consultation with the US FDA
• F14 (mdc-CWM) is the third product using MedinCell’s proprietary BEPO® technology to reach or complete a Phase 3 clinical trial